The human cytomegalovirus

Pharmacology and Therapeutics

Volumn 98, Issue 3, 2003, Pages 269-297

  Landolfo, Santo ^a   Gariglio, Marisa ^b   Gribaudo, Giorgio ^a   Lembo, David ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antiviral therapy; Diagnosis; Epidemiology; Gene expression; HCMV; Transplant

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BENZIMIDAZOLE RIBOSIDE; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; DOUBLE STRANDED DNA; FOMIVIRSEN; FOSCARNET; PLACEBO; PROBENECID; PYROPHOSPHORIC ACID DERIVATIVE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGRAFT; AUTOPSY; BONE MARROW SUPPRESSION; BREAST DUCT; BREAST FEEDING; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DELIVERY; DIGESTIVE SYSTEM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE SYSTEM; INFECTION CONTROL; LIPID BILAYER; LOW DRUG DOSE; MOTHER; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REINFECTION; RESPIRATORY SYSTEM; REVIEW; SYNTHESIS; TREATMENT OUTCOME; UROGENITAL SYSTEM; VIRUS GENOME; VIRUS NUCLEOCAPSID; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION;

EID: 0038362228     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(03)00034-2     Document Type: Review

References (298)

1. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., Best A.M. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 171:1995;26-32.
2. Adler S.P., Hempfling S.H., Starr S.E., Plotkin S.A., Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J. 17:1998;200-206.
3. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., Dellamonica P., Best A.M., Zahradnik J., Pincus S., Berencsi K., Cox W.I., Gyulai Z. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis. 180:1999;843-846.
4. Aduma P., Connelly M.C., Srinivas M.C., Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol. 47:1995;816-822.
5. Ahn J.H., Jang W.J., Hayward G.S. The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein associated nuclear bodies (PODs or ND10). J Virol. 73:1999;10471-10548.
6. Anderson K.P., Fox M.C., Brown-Driver V., Martin M.J., Azad R.F. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother. 40:1996;2004-2011.
7. Anonymous Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med. 326:1992;213-220. Erratum: N Engl J Med 326, 1172 (1992).
8. Aono T., Kondo K., Miyoshi H., Tanaka-Taya K., Kondo M., Osugi Y., Hara J., Okada S., Yamanishi K. Monitoring of human cytomegalovirus infections in pediatric bone marrow transplant recipients by nucleic acid sequence-based amplification. J Infect Dis. 178:1998;1244-1249.
9. Apperley J.F., Goldman J.M. Cytomegalovirus: biology, clinical features and methods for diagnosis. Bone Marrow Transplant. 3:1988;253-264.
10. Azad R.F., Driver V.B., Tanaka K., Crooke R.M., Anderson K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobiol Agents Chemother. 37:1993;1945-1954.
11. Baldanti F., Silini E., Sarasini A., Talarico C.L., Stanat S.C., Biron K.K., Furione M., Bono F., Palu G., Gerna G. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol. 69:1995;796-800.
12. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., Silini E., Gerna G. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol. 70:1996;1390-1395.
13. Baldanti F., Simoncini L., Talarico C.L., Sarasini A., Biron K.K., Gerna G. Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient. AIDS. 12:1998;816-818.
14. Baldick C.J., Shenk T. Proteins associated with purified human cytomegalovirus particles. J Virol. 70:1996;6097-6105.
15. Baldick C.J., Marchini A., Patterson C.E., Shenk T. Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J Virol. 71:1997;4400-4408.
16. Becroft D.M.O. Prenatal cytomegalovirus infection: epidemiology, pathology, and pathogenesis. Rosenberg H.S., Bernstein J. Perspective in Pediatric Pathology. 1981;203-241 Masson Press, New York.
17. Benedetti E., Mihalov M., Asolati M., Kirby J., Dunn T., Raofi V., Fontaine M., Pollak R. A prospective study of the predictive value of polymerase chain reaction assay for cytomegalovirus in asymptomatic kidney transplant recipients. Clin Transplant. 12:1998;391-395.
18. Beninga J., Kropff B., Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol. 76:1995;153-160.
19. Benson J.D., Huang E.-S. Human cytomegalovirus induces expression of cellular topoisomerase II. J Virol. 64:1990;9-15.
20. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S., Plotkin S. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis. 183:2001;1171-1179.
21. Bissinger A.L., Singzer C., Kaiserling E., Jahn G. Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol. 67:2002;200-206.
22. Blackburn N.K., Besselaar T.G., Schoub B.D., O'Connell K.F. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity. J Med Virol. 33:1991;6-9.
23. Blanshard C., Benhamou Y., Dohin E., Lernestedt J.O., Gazzard B.G., Katlama C. Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis. 172:1995;622-628.
24. Blok M.J., Goossens V.J., Vanherle S.J., Top B., Tacken N., Middeldorp J.M., Christiaans M.H., van Hooff J.P., Bruggeman C.A. Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipients by nucleic acid sequence-based amplification. J Clin Microbiol. 36:1998;1341-1346.
25. Bodaghi B., Jones T.R., Zipeto D., Vita C., Sun L., Laurent L., Arenzana-Seisdedos F., Virelizier J.L., Michelson S. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med. 188:1998;855-866.
26. Bodeus M., Feyder S., Goubau P. Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infection in pregnant women. Clin Diagn Virol. 9:1998;9-16.
27. Boeckh M., Bowden R. Cytomegalovirus infection in marrow transplantation. Cancer Treat Res. 76:1995;97-136.
28. Boppana S.B., Britt W.J. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology. 222:1996;293-296.
29. Boppana S.B., Pass R.F., Britt W.J., Stagno S., Alford C.A. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis. 11:1992;93-99.
30. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 41:1985;521-530.
31. Bowen E.F., Sabin C.A., Wilson P., Griffiths P.D., Davey C.C., Johnson M.A., Emery V.C. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS. 11:1997;889-893.
32. Boyle K.A., Pietropaolo R.L., Compton T. Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway. Mol Cell Biol. 19:1999;3607-3613.
33. Bresnahan W.A., Shenk T. A subset of viral transcripts packaged within human cytomegalovirus particles. Science. 288:2000;2373-2376.
34. Bresnahan W.A., Shenk T. UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells. Proc Natl Acad Sci USA. 97:2000;14506-14511.
35. Bresnahan W.A., Boldogh I., Thompson E.A., Albrecht T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology. 224:1996;150-160.
36. Bresnahan W.A., Thompson E.A., Albrecht T. Human cytomegalovirus infection results in altered Cdk2 subcellular localization. J Gen Virol. 78:1997;1993-1997.
37. Britt W.J. Vaccines against human cytomegalovirus: time to test. Trends Microbiol. 4:1996;34-38.
38. Britt W.J., Mach M. Human cytomegalovirus glycoproteins. Intervirology. 39:1996;401-412.
39. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 64:1990;1079-1085.
40. Brosgart C.L., Louis T.A., Hillman D.W., Craig C.P., Alston B., Fisher E., Abrams D.I., Luskin-Hawk R.L., Sampson J.H., Ward D.J., Thompson M.A., Torres R.A. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 12:1998;269-277.
41. Browne E.P., Wing B., Coleman D., Shenk T. Altered cellular mRNA levels in human cytomegalovirus infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol. 75:2001;12319-12330.
42. Burton G.J., Watson A.L. The structure of the human placenta: implications for initiating and defending against virus infections. Rev Med Virol. 7:1997;219-228.
43. Butcher S.J., Aitken J., Mitchell J., Gowen B., Dargan D.J. Structure of the human cytomegalovirus B capsid by electron microscopy and image reconstruction. J Struct Biol. 124:1998;70-76.
44. Caswell R., Hagemeier C., Chiou C.-J., Hayward G., Kouzarides T., Sinclair J.H. The human cytomegalovirus 86K immediate early (IE2) protein requires the basic region of the TATA-box binding protein (TBP) for binding, and interacts with TBP and transcription factor TFIIB via region of IE2 required for transcriptional regulation. J Gen Virol. 74:1993;2691-2698.
45. Cavallo R., Lembo D., Gribaudo G., Landolfo S. Murine cytomegalovirus infection induces cellular folylpolyglutamate synthetase activity in quiescent cells. Intervirology. 44:2001;224-226.
46. Cha T.A., Tom E., Kemble G.W., Duke G.M., Mocarski E.S., Spaete R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol. 70:1996;78-83.
47. Chambers J., Angulo A., Amaratunga D., Guo H., Jiang Y., Wan J.S., Bittner A., Frueh K., Jackson M.R., Peterson P.A., Erlander M.G., Ghazal P. DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J Virol. 73:1999;5757-5766.
48. Chavez-de la Paz E., Arevalo J.F., Kirsch L.S., Munguia D., Rahhal F.M., De Clercq E., Freeman W.R. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology. 104:1997;539-544. Erratum: Ophthalmology, 104, 1063 (1997).
49. Chee M.S., Bankier A.T., Beck S., Bohni R., Brown C.M., Cerny R., Horsnell T., Hutchison C.A. III, Kouzarides T., Martignetti J.A., Preddie E., Satchwell S.C., Tomlinson P., Weston K.M., Barrell B.G. Analysis of the protein-coding content of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 154:1990;125-169.
50. Chee M.S., Satchwell S.C., Preddie E., Weston K.M., Barrell B.G. Human cytomegalovirus encodes three G protein-coupled receptor homologues. Nature. 344:1990;774-777.
51. Cherrington J.M., Khoury E.L., Mocarski E.S. Human cytomegalovirus IE2 negatively regulates α gene expression via a short target sequence near the transcription start site. J Virol. 65:1991;887-896.
52. Cherrington J.M., Miner R., Hitchcock M.J., Lalezari J.P., Drew W.L. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug. J Infect Dis. 173:1996;987-992.
53. Cherrington J.M., Allen A.S.J.W., Mulato S., Miner R., Drew W.L., Chen M.S. Sensitivities of human cytomegalovirus (HCMV) clinical isolates to cidofovir. Antiviral Res. 26:1998;A319.
54. Cheung T.W., Teich S.A. Cytomegalovirus infection in patients with HIV infection. Mt Sinai J Med. 66:1999;113-124.
55. Chou S.W., Dennison K.M. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis. 163:1991;1229-1234.
56. Chou S., Guentzel S., Michels K.R., Miner R.C., Drew W.L. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis. 172:1995;239-242.
57. Chrisp P., Clissold S.P. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs. 41:1991;104-129.
58. Chulay J., Biron K., Wang L., Underwood M., Chamberlain S., Frick L., Good S., Davis M., Harvey R., Townsend L., Drach J., Koszalka G. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv Exp Med Biol. 458:1999;129-134.
59. Compton T., Nowlin D.M., Cooper N.R. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology. 193:1993;834-841.
60. Courcelle C.T., Courcelle J., Prichard M.N., Mocarski E.S. Requirement for uracil-DNA glycosylase during the transition to late-phase cytomegalovirus DNA replication. J Virol. 75:2001;7592-7601.
61. Cundy K.C., Li Z.H., Lee A. Effect of concomitant probenecid on the tissue distribution and urinary excretion of HPMPC in preclinical models. Pharm Res. 11:1994;S449.
62. Davignon J.L., Clement D., Alriquet J., Michelson S., Davrinche C. Analysis of the proliferative T cell response to human cytomegalovirus major immediate-early protein (IE1): phenotype, frequency and variability. Scand J Immunol. 41:1995;247-255.
63. De Clercq E. Antiviral agents that are active against CMV: potential of cidofovir for the treatment of CMV and other virus infections. Scholz M., Rabenau H.F., Doerr H.W., Cinatl J. Jr. CMV-Related Immunopathology, Monographs in Virology. Vol. 21:1998;193-214 Karger, Basel.
64. De Smet M.D., Meenken C.J., van den Horn G.J. Fomivirsen a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm. 7:1999;189-198.
65. Dieterich D.T., Kotler D.P., Busch D.F., Crumpacker C., Du Mond C., Dearmand B., Buhles W. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis. 167:1993;278-282.
66. 1/S transition. J Virol. 71:1997;1629-1634.
67. Donaldson P.T., Alexander G.J., O'Grady J., Neuberger J., Portmann B., Thick M., Davis H., Calne R.Y., Williams R. Evidence for an immune response to HLA class I antigens in the vanishing-bile duct syndrome after liver transplantation. Lancet. 1:1987;945-948.
68. Drew W.L., Miner R.C., Busch D.F., Follansbee S.E., Gullett J., Mehalko S.G., Gordon S.M., Owen W.F. Jr., Matthews T.R., Buhles W.C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 163:1991;716-719.
69. Drew W.L., Ives D., Lalezari J.P., Crumpacker C., Follansbee S.E., Spector S.A., Benson C.A., Friedberg D.N., Hubbard L., Stempien M.J., Shadman A., Buhles W. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 333:1995;615-620.
70. Drulak M.W., Malinoski F.J., Fuller S.A., Stewart S.S., Hoskin S., Duliege A.M., Sekulovich R., Burke R., Winston S. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. Viral Immunol. 13:2000;49-56.
71. Dworsky M., Yow M., Stagno S., Pass R.F., Alford C. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics. 72:1983;295-299.
72. Einsele H., Ehninger G., Hebart H., Wittkowski K.M., Schuler U., Jahn G., Mackes P., Herter M., Klingebiel T., Loffler J. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:1995;2815-2820.
73. Elek S.D., Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet. i:1974;1-5.
74. Emery V.C. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol. 11:2001;83-86.
75. Endresz V., Kari L., Berencsi K., Kari C., Gyulai Z., Jeney C., Pincus S., Rodeck U., Meric C., Plotkin S.A., Gonczol E. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine. 17:1999;50-58.
76. Endresz V., Burian K., Berencsi K., Gyulai Z., Kari L., Horton H., Virok D., Meric C., Plotkin S.A., Gonczol E. Optimization of DNA immunization against human cytomegalovirus. Vaccine. 19:2001;3972-3980.
77. Erice A., Chou S., Biron K.K., Stanat S.C., Balfour H.H. Jr., Jordan M.C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 320:1989;289-293.
78. Estes J.E., Huang E.-S. Stimulation of cellular thymidine kinase by human cytomegalovirus. J Virol. 24:1977;13-21.
79. Faber D.W., Wiley C.A., Lynn G.B., Gross J.G., Freeman W.R. Role of HIV and CMV in the pathogenesis of retinitis and retinal vasculopathy in AIDS patients. Invest Ophthalmol Vis Sci. 33:1992;2345-2353.
80. Fortunato E.A., Spector D.H. Regulation of human cytomegalovirus gene expression. Adv Virus Res. 54:1999;61-128.
81. Fortunato E.A., Sommer M.H., Yoder K., Spector D.H. Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J Virol. 71:1997;8176-8185.
82. Fortunato E.A., McElroy A.K., Sanchez V., Spector D.H. Exploitation of cellular signalling and regulatory pathways by human cytomegalovirus. Trends Microbiol. 8:2000;111-119.
83. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 326:1992;663-667.
84. Gallant J.E., Moore R.D., Richman D.D., Keruly J., Chaisson R.E. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis. 166:1992;1223-1227.
85. Gao J.L., Murphy P.M. Human cytomegalovirus open reading frame US28 encodes a functional β chemokine receptor. J Biol Chem. 269:1994;28539-28542.
86. Gerna G., Revello M.G., Percivalle E., Zavattoni M., Marea M., Battaglia M. Quantification of human Cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Mirobiol. 28:1990;2681-2688.
87. Gerna G., Zipeto D., Parea M., Revello M.G., Silini E., Percivalle E., Zavattoni M., Grossi P., Milanesi G. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis. 164:1991;488-498.
88. Gerna G., Baldanti F., Zavattoni M., Sarasini A., Percivalle E., Revello M.G. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res. 1:1992;333-345.
89. Gerna G., Revello M.G., Percivalle E., Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol. 30:1992;1232-1237.
90. Gerna G., Percivalle E., Revello M.G., Morini F. Correlation of quantitative human cytomegalovirus pp65- p72- and p150-antigenemia, viremia and circulating endothelial giant cells with clinical symptoms and antiviral treatment in immunocompromised patients. Clin Diagn Virol. 1:1993;47-59.
91. Gerna G., Baldanti F., Sarasini A., Furione M., Percivalle E., Revello M.G., Zipeto D., Zella D. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. Antimicrob Agents Chemother. 38:1994;38-44.
92. Gerna G., Furione M., Baldanti F., Sarasini A. Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol. 32:1994;709-717.
93. Gerna G., Furione M., Baldanti F., Percivalle E., Comoli P., Locatelli F. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br J Haematol. 91:1995;674-683.
94. Gerna G., d'Arminio Monforte A., Zavattoni M., Sarasini A., Testa L., Revello M.G., Moroni M. Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy. AIDS. 12:1998;118-120.
95. Gerna G., Zavattoni M., Baldanti F., Sarasini A., Chezzi L., Grossi P., Revello M.G. Human cytomegalovirus (HCMV) leukodnaemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation. 65:1998;1378-1385.
96. Gerna G., Baldanti F., Middeldorp J.M., Furione M., Zavattoni M., Lilleri D., Revello M.G. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol. 37:1999;902-911.
97. Gerna G., Baldanti F., Lilleri D., Parea M., Alessandrino E., Pagani A., Locatelli F., Middeldorp J., Revello M.G. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Microbiol. 38:2000;1845-1853.
98. Gerna G., Percivalle E., Baldanti F., Sozzani S., Lanzarini P., Genini E., Lilleri D., Revello M.G. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol. 74:2000;5629-5638.
99. Gibson W. Structure and assembly of the virion. Intervirology. 39:1996;389-400.
100. Gilbert G.L., Hayes K., Hudson I.L., James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet. i:1989;1228-1231.
101. Gilbert M.J., Riddell S.R., Plachter B., Greenberg P.D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 383:1996;720-722.
102. Gleaves C.A., Smith T.F., Shuster E.A., Pearson G.R. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol. 19:1984;917-919.
103. Goldmacher V.S. vMIA, a viral inhibitor of apoptosis targeting mitochondria. Biochimie. 84:2002;177-185.
104. Gonczol E., Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther. 1:2001;401-412.
105. Gonczol E., deTaisne C., Hirka G., Berencsi K., Lin W.C., Paoletti E., Plotkin S. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine. 9:1991;631-637.
106. Goodrich J.M., Mori M., Gleaves C.A., Du Mond C., Cays M., Ebeling D.F., Buhles W.C., DeArmond B., Meyers J.D. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 325:1991;1601-1607.
107. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 118:1993;173-178.
108. Gozlan J., Laporte J.P., Lesage S., Labopin M., Najman A., Gorin N.C., Petit J.C. Monitoring of cytomegalovirus infection and disease in bone marrow recipients by reverse transcription-PCR and comparison with PCR and blood and urine cultures. J Clin Microbiol. 34:1996;2085-2088.
109. Grangeot-Keros L., Mayaux M.J., Lebon P., Freymuth F., Eugene G., Stricker R., Dussaix E. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J Infect Dis. 175:1997;944-946.
110. Gretch D.R., Kari B., Rasmussen L., Gehrz R.C., Stinski M.F. Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. J Virol. 62:1988;875-881.
111. Gribaudo G., Riera L., Lembo D., De Andrea M., Gariglio M., Rudge T.L., Johnson L.F., Landolfo S. Murine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replication. J Virol. 74:2000;4979-4987.
112. Gribaudo G., Riera L., Rudge T.L., Caposio P., Johnson L.F., Landolfo S. Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts. J Gen Virol. 83:2002;2983-2993.
113. Griffiths P.D. Cytomegalovirus. Zuckerman A.J., Banatvala J.E., Pattison J.R. Principles and Practice of Clinical Virology. 2000;79-116 John Wiley and Sons, London.
114. Griffiths P.D., Panjwani D.D., Stirk P.R., Ball M.G., Ganczakowski M., Blacklock H.A., Prentice H.G. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet. ii:1984;1242-1245.
115. Grossi P., Minoli L., Percivalle E., Irish W., Vigano M., Gerna G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation. 59:1995;847-851.
116. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., Meric C., Plotkin S., Gonczol E., Berencsi K. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis. 181:2000;1537-1546.
117. Hagemeier C., Walker S., Caswell R., Kouzarides T., Sinclair J.H. The 72K IE1 and 80K IE2 proteins of human cytomegalovirus independently trans-activate the c-fos, c-myc and hsp70 promoter via basal promoter elements. J Gen Virol. 73:1992;2385-2393.
118. Hagemeier C., Walker S., Caswell R., Kouzarides T., Sinclair J.H. The human cytomegalovirus 80-kilodalton but not the 72-kilodalton immediate-early protein transactivates heterologous promoters in a TATA box-dependent mechanism and interacts directly with TFIID. J Virol. 66:1992;4452-4456.
119. Hagemeier C., Caswell R., Hayhurst G., Sinclair J.H., Kouzarides T. Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J. 13:1994;2897-2903.
120. Hahn G., Jores R., Mocarski E. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA. 95:1998;3937-3942.
121. Halwachs-Baumann G., Wilders-Trucshnig M., Desoye G., Hahn T., Kiesel L., Klingel K., Rieger P., Jahn G., Sinzger C. Human trophoblast cells are permissive to the complete replicative cycle of human cytomegalovirus. J Virol. 72:1998;7598-7602.
122. Harrison C.J., Britt W.J., Chapan N.M., Mullican J., Tracy S. Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis. 172:1995;1212-1220.
123. 1 phase of the cell cycle. Proc Natl Acad Sci USA. 97:2000;2692-2696.
124. Hayhurst G.P., Bryant L.A., Caswell R.C., Walker S.M., Sinclair J.H. CCAAT box-dependent activation of the TATA-less human DNA polymerase α promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein. J Virol. 69:1995;182-188.
125. He H., Rinaldo C.R. Jr., Morel P.A. T cell proliferative responses for five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development. J Gen Virol. 76:1995;1603-1610.
126. Hemmings D.G., Kilani R., Nyukiforuk C., Preiksaitis J., Guibert L.J. Permissive cytomegalovirus infection of primary villous term and first trimester trophoblasts. J Virol. 72:1998;4970-4979.
127. Hengel H., Brune W., Koszinowski U.H. Immune evasion by cytomegalovirus-survival strategies of a highly adapted opportunist. Trends Microbiol. 6:1998;190-197.
128. Herrera G.A., Alexander R.W., Cooly C.F., Luke R.G., Kelly D.R., Curtis J.J., Gockerman J.P. Cytomegalovirus glomerulopathy: a controversial lesion. Kidney Int. 29:1986;725-733.
129. Ho M. Cytomegalovirus. Mandell G.L., Bennet J.E., Dolin R. Principles and Practices of Infectious Diseases. 1991;1351-1364 Churchill Livingstone, New York.
130. Ho H.-T., Woods K.L., Bronson J.J., De Boeck H., Martin J.C., Hitchcock M.J. Intracellular metabolism of the antiherpes agent (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)-cytosine. Mol Pharmacol. 41:1992;97-202.
131. Hobom U., Brune W., Messerle M., Hahn G., Koszinowski U.H. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoproteins genes. J Virol. 74:2000;7720-7729.
132. Huber M.T., Compton T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol. 72:1998;8191-8197.
133. Isom H.C. Stimulation of ornithine decarboxylase by human cytomegalovirus. J Gen Virol. 42:1979;265-278.
134. Jabs D.A., Enger C., Dunn J.P., Forman M. Cytomegalovirus retinitis and viral resistance: 4. Ganciclovir resistance. J Infect Dis. 177:1998;770-773.
135. Jabs D.A., Enger C., Forman M., Dunn J.P. Incidence of foscarnet resistance and cidofovir resistance in in patients treated for cytomegalovirus retinitis. Antimicrob Agents Chemother. 42:1998;2240-2244.
136. Jacobson M.A. Cytomegalovirus retinitis: new developments in prophylaxis and therapy. AIDS Clin Rev. 1997-1998;249-269.
137. Jassal S.V., Roscoe J.M., Zaltzman J.S., Mazzulli T., Krajden M., Gadawski M., Cattran D.C., Cardella C.J., Albert S.E., Cole E.H. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol. 9:1998;1697-1708.
138. Jault F.M., Jault J.M., Ruchti F., Fortunato E.A., Clark C., Corbeil J., Richman D.D., Spector D.H. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol. 69:1995;6697-6704.
139. Johnson R.A., Yurochko A.D., Poma E.E., Zhu L., Huang E.-S. Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences. J Gen Virol. 80:1999;1293-1303.
140. Jones T.R., Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol. 71:1997;2970-2979.
141. Jones T.R., Wiertz E.J., Sun L., Fish K.N., Nelson J.A., Ploegh H.L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA. 93:1996;11327-11333.
142. Jonjic S., Pavic I., Lucin P., Rukavina D., Koszinowski U.H. Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ lymphocytes. J Virol. 64:1990;5457-5464.
143. Jupp R., Hoffmann S., Stenberg R.M., Nelson J.A., Ghazal P. Human cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via a specific region distinct from the autorepression domain. J Virol. 67:1993;7539-7546.
144. Kahl M., Siegel-Axel D., Stenglein S., Jahn G., Sinzger C. Efficient lytic infection of human arterial endothelial cells by human cytomegalovirus strains. J Virol. 74:2000;7628-7635.
145. Kalejta R.F., Shenk T. Manipulation of the cell cycle by human cytomegalovirus. Front Biosc. 7:2002;295-306.
146. Kari B., Li W., Cooper J., Goertz R., Radeke B. The human cytomegalovirus UL100 gene encodes the gC-II glycoproteins recognized by group 2 monoclonal antibodies. J Gen Virol. 75:1994;3081-3086.
147. Karlin S., Mocarski E.S., Schachtel G.A. Molecular evolution of herpesviruses: genomic and protein sequence comparisons. J Virol. 68:1994;1886-1902.
148. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol. 73:1999;8179-8184.
149. Kidd I.M., Fox J.C., Pillay D., Charman H., Griffiths P.D., Emery V.C. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation. 56:1993;867-871.
150. Knox K.K., Drobyski W.R., Carrigan D.R. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet. ii:1991;1292-1293.
151. Kondo K., Kaneshima H., Mocarski E.S. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA. 91:1994;11879-11883.
152. Koszinowski U.H., Del Val M., Reddehase M.J. Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol. 154:1990;189-215.
153. Lalezari J.P., Holland G.N., Kramer F., McKinley G.F., Kemper C.A., Ives D.V., Nelson R., Hardy W.D., Kuppermann B.D., Northfelt D.W., Youle M., Johnson M., Lewis R.A., Weinberg D.V., Simon G.L., Wolitz R.A., Ruby A.E., Stagg R.J., Jaffe H.S. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Def Syndr Hum Retrovirol. 17:1998;339-344.
154. Lam K.M., Oldenburg N., Khan M.A., Gaylore V., Mikhail G.W., Strouhal P.D., Middeldorp J.M., Banner N., Yacoub M. Significance of reverse transcription polymerase chain reaction in the detection of human cytomegalovirus gene transcripts in thoracic organ transplant recipients. J Heart Lung Transplant. 17:1998;555-565.
155. Landini M.P., Michelson S. Human cytomegalovirus proteins. Melnick J.L. Progress in Medical Virology. 1988;152-185 Karger, Basel.
156. Landini M.P., Rossier E., Schmitz H. Antibodies to human cytomegalovirus structural polypeptides during primary infection. J Virol Methods. 22:1988;309-317.
157. Lazzarotto T., Spezzacatena P., Varani S., Gabrielli L., Pradelli P., Guerra B., Landini M.P. Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin Diagn Lab Immunol. 6:1999;127-129.
158. Leach C.T., Cherry J.D., English P.A., Hennessey K., Giorgi J.V., Visscher B.R., Dudley J.P., Detels R. The relationship between T-cells and CMV infection in asymptomatic HIV-1 antibody-positive homosexual men. J Acquir Immune Def Syndr Hum Retrovirol. 6:1993;407-413.
159. Lembo D., Gribaudo G., Cavallo R., Riera L., Angeretti A., Hertel L., Landolfo S. Human cytomegalovirus stimulates cellular dihydrofolate reductase activity in quiescent cells. Intervirology. 42:1999;30-36.
160. Lembo D., Gribaudo G., Hofer A., Riera L., Cornaglia M., Mondo A., Angeretti A., Gariglio M., Thelander L., Landolfo S. Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts. J Virol. 74:2000;11557-11565.
161. Limaye A.P., Corey L., Koelle D.M., Davis C.L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 356:2000;645-649.
162. Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 185:2002;20-27.
163. Littler E., Stuart A.D., Chee M.S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 358:1992;160-162.
164. Liu B., Stinski M.F. Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. J Virol. 66:1992;4434-4444.
165. Liu Y.N., Curtsinger J., Donahue P.R., Klaus A., Optiz G., Cooper J., Karr R.W., Bachs F.H., Gehrz R.C. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93. J Gen Virol. 74:1993;2207-2214.
166. Loebe M., Schuler S., Zais O., Warnecke H., Fleck E., Hetzer R. Role of cytomegalovirus infection in the development of coronary disease in the transplanted hearth. J Heart Transplant. 9:1990;707-711.
167. 1 to S. J Virol. 70:1996;8850-8857.
168. 1 phase of the cell cycle. J Virol. 73:1999;676-683.
169. Lukac D.M., Harel N.Y., Tanese N., Alwine J.C. TAF-like functions of human cytomegalovirus immediate-early proteins. J Virol. 71:1997;7227-7239.
170. Lurain N.S., Spafford L.E., Thompson K.D. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol. 68:1994;4427-4431.
171. Macdonald P.S., Keogh A.M., Marshman D., Richens D., Harvison A., Kaan A.M., Spratt P.M. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant. 14:1995;32-38.
172. Machold R.P., Wiertz F.J., Jones T.R., Ploegh H.L. The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J Exp Med. 185:1997;363-366.
173. Marchini A., Liu H., Zhu H. Human cytomegalovirus with IE2 (UL122) deleted fails to express early lytic genes. J Virol. 75:2001;1870-1878.
174. Margolis M.J., Pajovic S., Wong E.L., Wade M., Jupp R., Nelson J.A., Clifford Azizkhan J. Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J Virol. 69:1995;7759-7767.
175. Marshall G.S., Rabalais G.P., Stout G.G., Waldeyer S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis. 165:1992;381-384.
176. Masse M.J., Karlin S., Schachtel G.A., Mocarski E.S. Human cytomegalovirus origin of DNA replication (oriLyt) resides within a highly complex repetitive region. Proc Natl Acad Sci USA. 89:1992;5246-5250.
177. Masur H., Whitcup S.M., Cartwright C., Polis M., Nussenblatt R. Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med. 125:1996;126-136.
178. McVoy M.A., Adler S.P. Human cytomegalovirus DNA replicates after early circularization by concatemer formation, and inversion occurs within concatemer. J Virol. 68:1994;1040-1051.
179. Meier J.L., Stinski M.F. Regulation of human cytomegalovirus immediate-early gene expression. Intervirology. 39:1996;331-342.
180. Meier J.L., Stinski M.F. Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells. J Virol. 71:1997;1246-1255.
181. Merigan T.C., Renlund D.G., Keay S., Bristow M.R., Starnes V., O'Connell J.B., Resta S., Dunn D., Gamberg P., Ratkovec R.M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 326:1992;1182-1186.
182. Mettenleiter T.C. Herpesvirus assembly and egress. J Virol. 76:2002;1537-1547.
183. Miller W.J., McCullough J., Balfour H.H., Haake R.J., Ramsay N.K., Goldman A., Bowman R., Kersey J. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. 7:1991;227-234.
184. Mocarski E.S. Cytomegalovirus and their replication. Fields B.N., Knipe D.M., Howley P.M. Virology. 1996;2447-2492 Lippincott-Raven, Philadelphia.
185. Mocarski E.S. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 10:2002;332-339.
186. Mocarski E.S., Courcelle C.T. Cytomegalovirus and their replication. Knipe D., Howley P. Fields Virology. 2001;2629-2673 Lippincott, Williams and Wilkins, Philadelphia.
187. Mocarski E.S., Kemble G.W., Lyle J.M., Greaves R.F. A deletion mutant in the human cytomegalovirus gene encoding IE1 (491 aa) is replication defective due to a failure in autoregulation. Proc Natl Acad Sci USA. 94:1996;11321-11326.
188. Murphy E.A., Streblow D.N., Nelson J.A., Stinski M.F. The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J Virol. 74:2000;7108-7118.
189. Nelson J.A., Gnann J.W., Ghazal P. Regulation and tissue-specific expression of human cytomegalovirus. Curr Top Microbiol Immunol. 154:1990;75-100.
190. Nesmith J.D., Pass R.F. Cytomegalovirus infection in adolescent. Overturf G.D., Jacobs R.F. Adolescent Medicine: State of the Art Reviews. Viral Infections in Adolescents. 1995;79-90 Hanley and Belfus, Philadelphia.
191. Novotny J., Rigoutsos I., Coleman D., Shenk T. In silico structural and functional analysis of the human cytomegalovirus (HHV5) genome. J Mol Biol. 310:2001;1151-1166.
192. O'Sullivan C.E., Drew W.L., McMullen D.J., Miner R., Lee J.Y., Kaslow R.A., Lazar J.G., Saag M.S. Decrease of cytomegalovirus replication in human immunodeficiency virus-infected patients after treatment with highly active antiretroviral therapy. J Infect Dis. 180:1999;847-849.
193. Pajovic S., Wong E.L., Black A.R., Azizkhan C.J. Identification of a viral kinase that phosphorylates specific E2Fs and pocket proteins. Mol Cell Biol. 17:1997;6459-6464.
194. Palestine A.G., Polis M.A., De Smet M.D., Baird B.F., Falloon J., Kovacs J.A., Davey R.T., Zurlo J.J., Zunich K.M., Davis M.et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 115:1991;665-673.
195. Pass R.F. Epidemiology and transmission of cytomegalovirus infection. J Infect Dis. 152:1985;243-256.
196. Pass R.F. Immunization strategy for prevention of congenital cytomegalovirus infection. Infect Agents Dis. 5:1996;240-244.
197. Pass R.F. Cytomegalovirus. Knipe D., Howley P. Fields Virology. 2001;2675-2705 Lippincott, Williams and Wilkins, Philadelphia.
198. Pass R.F., Boppana S. Cytomegalovirus. Jeffries D.J., Hudson C.N. Viral Infections in Obstetrics and Gynaecology. 1999;35-56 Arnold, New York.
199. Pass R.F., Stagno S., Britt W.J. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J Infect Dis. 148:1983;953-961.
200. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., Burke R.L. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 180:1999;970-975.
201. Penfold M.E., Mocarski E.S. Formation of cytomegalovirus DNA replication compartments defined by localization of viral proteins and DNA synthesis. Virology. 239:1997;46-61.
202. Penfold M.E., Dairaghi D.J., Duke G.M., Saedurup N., Mocarski E.S., Kemble G.W., Schall T.J. Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci USA. 96:1999;9839-9844.
203. Pepperl S., Munster J., Mach M., Harris J.R., Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol. 74:2000;6132-6146.
204. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Def Syndr Hum Retrovirol. 5:1992;1069-1074.
205. Peterson P.K., Balfour H.H. Jr., Marker S.C., Fryd D.S., Howard R.J., Simmons R.L. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine. 59:1980;283-300.
206. Phillips C.A., Fanning W.L., Gump D.W. Cytomegalovirus in immunologically normal adults. JAMA. 238:1977;2299-2300.
207. Pizzorno M.C., Hayward G.S. The IE2 gene products of human cytomegalovirus specifically down-regulate expression from the major immediate-early promoter through a target sequence located near the cap site. J Virol. 64:1990;6154-6165.
208. Plachter B., Sinzger C., Jahn G. Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res. 46:1996;195-261.
209. Plotkin S.A., Furukawa T., Zygraich N., Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infect Immun. 12:1975;521-527.
210. Plotkin S.A., Farquhar J., Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis. 134:1976;470-475.
211. Plotkin S.A., Smiley M.L., Friedman H.M., Starr S.E., Fleisher G.R., Wlodaver C., Dafoe D.C., Friedman A.D., Grossman R.A., Barker C.F. Towne-vaccine induced prevention of cytomegalovirus disease after renal transplants. Lancet. i:1984;528-530.
212. Plotkin S.A., Starr S.E., Friedman H.M., Gonczol E., Weibel R.E. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis. 159:1989;860-865.
213. Plotkin S.A., Starr S.E., Friedman H.M., Brayman K., Harris S., Jackson S., Tustin N.B., Grossman R., Dafoe D., Barker C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med. 114:1991;525-531.
214. Plotkin S.A., Higgins R., Kurtz J.B., Morris P.J., Campbell D.A. Jr., Shope T.C., Spector S.A., Dankner W.M. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 58:1994;1176-1178.
215. Polic B., Jonjic S., Pavic I., Crnkovic I., Zorica I., Hengel H., Lucin P., Koszinowski U.H. Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol. 77:1996;217-225.
216. Polis M.A., Spooner K.M., Baird B.F., Manischewitz J.F., Jaffe H.S., Fisher P.E., Falloon J., Davey R.T.J., Kovacs J.A., Walker R.E., Whitcup S.M., Nussenblatt R.B., Lane H.C., Masur H. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 39:1995;882-886.
217. Pollard A.B. Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation. Pediatr Infect Dis J. 7:1988;97-102.
218. Poma E.E., Kowalik T.F., Zhu L., Sinclair J.H., Huang E.-S. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter. J Virol. 70:1996;7867-7877.
219. Rapp M., Messerle M., Buhler B., Tannheimer M., Keil G.M., Koszinowski U.R. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol. 66:1992;4399-4406.
220. Rawlinson W.D., Farrell H.E., Barrell B.G. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol. 70:1996;8833-8849.
221. Reddehase M.J., Balthesen M., Rapp M., Jonjic S., Pavic I., Koszinowski U.H. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med. 179:1994;185-193.
222. Reed E.C., Bowden R.A., Dandliker P.S., Lilleby K.E., Meyers J.D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 109:1988;783-788.
223. Rene E., Marche C., Chevalier T., Rouzioux C., Regnier B., Saimot A.G., Negesse Y., Matheron S., Leport C., Wolff B. Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. Dig Dis Sci. 33:1988;741-750.
224. Revello M.G., Percivalle E., Zavattoni M., Parea M., Grossi P., Gerna G. Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients. J Med Virol. 29:1989;88-93.
225. Revello M.G., Baldanti F., Furione M., Sarasini A., Percivalle E., Zavattoni M., Gerna G. Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. J Med Virol. 47:1995;462-466.
226. Revello M.G., Zavattoni M., Furione M., Baldanti F., Gerna G. Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin Mirobiol. 37:1999;3350-3352.
227. Revello M.G., Lilleri D., Zavattoni M., Stronati M., Bollani L., Middeldorp J.M., Gerna G. Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns. J Infect Dis. 184:2001;1078-1081.
228. Reynolds D.W., Stagno S., Hosty T.S., Tiller M., Alford C.A. Jr. Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med. 289:1973;1-5.
229. Richardson W.P., Colvin R.B., Cheeseman S.H., Tolkoff-Rubin N.E., Herrin J.T., Cosimi A.B., Collins A.B., Hirsch M.S., McCluskey R.T., Russell P.S., Rubin R.H. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med. 305:1981;57-63.
230. Riddell S.R., Rabin M., Geballe A.P., Britt W.J., Greenberg P.D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol. 146:1991;2795-2804.
231. Riera L., Gariglio M., Valente G., Mullbacher A., Museteanu C., Landolfo S., Simon M.M. Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection. Eur J Immunol. 30:2000;1350-1355.
232. Riera L., Gariglio M., Pagano M., Gaiola O., Simon M.M., Landolfo S. Control of murine cytomegalovirus replication in salivary glands during acute infection is independent of the Fas ligand/Fas system. Microbiologica. 24:2001;231-238.
233. Romanowski M.J., Garrido-Guerrero E., Shenk T. pIRS1 and pTRS1 are present in human cytomegalovirus virions. J Virol. 71:1997;5703-5705.
234. Rubie H., Attal M., Campardou A.M., Gayet-Mengelle C., Payen C., Sanguignol F., Calot J.P., Charlet J.P., Robert A., Huguet F. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant. 11:1993;209-214.
235. Rubin R.H. Preemptive therapy in immunocompromised hosts. N Engl J Med. 324:1991;1057-1059.
236. Rubin R.H. Infection in the organ transplant recipient. Rubin R.H., Young L.S. Clinical Approach to Infection in the Compromised Host. 1994;629-705 Plenum Medical Book Co. New York.
237. Rubin R.H., Tolkoff-Rubin N.E., Oliver D., Rota T.R., Hamilton J., Betts R.F., Pass R.F., Hillis W., Szmuness W., Farrell M.L. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation. 40:1985;243-249.
238. Ruutu P., Ruutu T., Volin L., Tukiainen P., Ukkonen P., Hovi T. Cytomegalovirus is frequently isolated in bronchoalveolar lavage fluid of bone marrow transplant recipients without pneumonia. Ann Intern Med. 112:1990;913-916.
239. Sadasivan B., Lehner P.J., Ortmann B., Spies T., Cresswell P. Role for clareticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity. 5:1996;103-114.
240. Saederup N., Lin Y.C., Dairaghi D.J., Schall T.J., Mocarski E.S. Cytomegalovirus-encoded β chemokine promotes monocyte-associated viremia in the host. Proc Natl Acad Sci USA. 96:1999;10881-10886.
241. Salvant B.S., Fortunato E.A., Spector D.H. Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J Virol. 72:1998;3729-3741.
242. Sanchez V., Sztul E., Britt W. Accumulation of virion tegument and envelope proteins in a stable cytoplasmatic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J Virol. 74:2000;975-986.
243. Sarisky R.T., Hayward G.S. Evidence that the UL84 gene product of human cytomegalovirus is essential for promoting oriLyt-dependent DNA replication and formation of replication compartments in cotransfection assays. J Virol. 70:1996;7398-7413.
244. Sayers M.H., Anderson K.C., Goodnough L.T., Kurtz S.R., Lane T.A., Pisciotto P., Silberstein L.E. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med. 116:1992;55-62.
245. Shamu C.E., Story C.M., Rapoport T.A., Ploegh H.L. The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate. J Cell Biol. 147:1999;45-58.
246. Shellam G.R., Allen J.E., Papdimitriou J.M., Bancroft J.M. Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proc Natl Acad Sci USA. 78:1981;5104-5108.
247. Simmen K.A., Singh J., Luukkonen B.G.M., Lopper M., Bittner A., Miller N.E., Jackson M.R., Compton T., Fruh K. Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad Sci USA. 98:2001;7140-7145.
248. Singh N., Yu V.L., Mieles L., Wagener M.M., Miner R.C., Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med. 120:1994;375-381.
249. Sinzger C., Jahn G. Human cytomegalovirus cell tropism and pathogenesis. Intervirology. 39:1996;302-319.
250. Sinzger C., Grefte A., Plachter B., Gouw A.S., The T.H., Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol. 76:1995;741-750.
251. Sinzger C., Plachter B., Grefte A., The T.H., Jahn G. Tissue macrophages are infected by human cytomegalovirus. J Infect Dis. 173:1996;240-245.
252. Sinzger C., Kahl M., Laib K., Klingel K., Rieger P., Plachter B., Jahn G. Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J Gen Virol. 81:2000;3021-3035.
253. Sison R.F., Holland G.N., MacArthur L.J., Wheeler N.C., Gottlieb M.S. Cytomegalovirus retinopathy as the initial manifestation of the acquired immunodeficiency syndrome. Am J Ophthalmol. 112:1991;243-249.
254. Skaletskaya A., Bartle L.M., Chittenden T., McCormick A.L., Mocarski E.S., Goldmacher V.S. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci USA. 98:2001;7829-7834.
255. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 176:1997;69-77.
256. Snydman D.R., Werner B.G., Heinze-Lacey B., Berardi V.P., Tilney N.L., Kirkman R.L., Milford E.L., Cho S.I., Bush H.L. Jr., Levey A.S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med. 317:1987;1049-1054.
257. Soderberg-Naucler C., Fish K.N., Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 91:1997;119-126.
258. + monocytes is differentiation dependent. J Virol. 75:2001;7543-7554.
259. Sommer M.H., Scully A.L., Spector D.H. Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein. J Virol. 68:1994;6223-6231.
260. Song Y., Stinski M.F. Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis. Proc Natl Acad Sci USA. 99:2002;2836-2841.
261. Spector S.A., Weingeist T., Pollard R.B., Dieterich D.T., Samo T., Benson C.A., Busch D.F., Freeman W.R., Montague P., Kaplan H.J., Keller L., Crager M., De Armond B., Buhles W., Feinberg J. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 168:1993;557-563.
262. Spector S.A., McKinley G.F., Lalezari J.P., Samo T., Andruczk R., Follansbee S., Sparti P.D., Havlir D.V., Simpson G., Buhles W., Wong R., Stempien M. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 334:1996;1491-1497.
263. Speir E., Modali R., Huang E.-S., Leon M.B., Shawl F., Finkel T., Epstein S.E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1993;391-394.
264. Stagno S., Reynolds D.W., Lakeman A., Charamella L.J., Alford C.A. Congenital cytomegalovirus infection: consecutive occurrence due to viruses with similar antigenic compositions. Pediatrics. 52:1973;788-794.
265. Stagno S., Reynolds D.W., Huang E.S., Thames S.D., Smith R.J., Alford C.A. Congenital cytomegalovirus infection: occurrence in an immune population. N Engl J Med. 296:1977;1254-1258.
266. Stagno S., Pass R.F., Dworsky M.E., Alford C.A. Jr. Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol. 25:1982;563-576.
267. Stagno S., Pass R.F., Cloud G., Britt W.J., Henderson R.E., Walton P.D., Veren D.A., Page F., Alford C.A. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 256:1986;1904-1908.
268. Stasiak P.C., Mocarski E.S. Transactivation of the human cytomegalovirus ICP36 gene promoter requires the α gene product TRS1 in addition to the IE1 and IE2. J Virol. 66:1992;1050-1058.
269. Story C.M., Furman M.H., Ploegh H.L. The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc Natl Acad Sci USA. 96:1999;8516-8521.
270. Stratta R.J., Wood R.P., Langnas A.N., Duckworth R.M., Shaefer M.S., Marujo W., Pillen T.J., Markin R.S., Shaw B.W. Jr. Donor selection for orthotopic liver transplantation: lack of an effect of gender or cytomegalovirus (CMV) status. Transplant Proc. 22:1990;410-413.
271. Streblow D.N., Orloff S.L., Nelson J.A. Do pathogens accelerate atherosclerosis? J Nutr. 13:2001;2798S-2804S.
272. Theiler R.N., Compton T. Characterization of the signal peptide processing and membrane association of human cytomegalovirus glycoprotein O. J Biol Chem. 276:2001;39226-39231.
273. The Vitravene Study Group A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 133:2002;467-474.
274. The Vitravene Study Group Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol. 133:2002;475-483.
275. Tomasec P., Braud V.M., Rickards C., Powell M.B., McSharry B.P., Gadola S., Cerundolo V., Borysiewicz L.K., McMichael A.J., Wilkinson G.W. Surface expression of HLA E an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science. 287:2000;1031-1033.
276. van den Berg A.P., van der Bij W., van Son W.J., Anema J., van der Giessen M., Schirm J., Tegzess A.M., The T.H. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation - a report of 130 consecutive patients. Transplantation. 48:1989;991-995.
277. van der Bij W., Schirm J., Torensma R., van Son W.J., Tegzess A.M., The T.H. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol. 26:1988;2531-2535.
278. van der Bij W., Torensma R., van Son W.J., Anema J., Schirm J., Tegzess A.M., The T.H. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol. 25:1988;179-188.
279. Vierling J.M., Fennel R.H. Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology. 5:1985;1076-1082.
280. Vinters H.V., Kwok M.K., Ho H.W., Anders K.H., Tomiyasu U., Wolfson W.L., Robert F. Cytomegalovirus in the nervous system of patients with the acquired immune deficiency syndrome. Brain. 112:1989;245-268.
281. Vochem M., Hamprecht K., Jahn G., Speer C.P. Transmission of cytomegalovirus to preterm infants through breast milk. Pediatr Infect Dis J. 17:1998;53-58.
282. Vogel J.-U., Scholz M., Cinatl J. Treatment of CMV diseases. Intervirology. 40:1998;357-367.
283. Wade M., Kowalik T.F., Mudryj M., Huang E.-S., Azizkhan J.C. E2F mediates dihydrofolate reducatse promoter activation and multiprotein complex formation in human cytomegalovirus infection. Mol Cell Biol. 12:1992;4364-4374.
284. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 333:1995;1038-1044.
285. Webster A., Philips A.N., Lee C.A., Janossy G., Kernoff P.B., Griffiths P.D. Cytomegalovirus (CMV) infection, CD4+ lymphocyte counts and the development of AIDS in HIV-1 infected haemophiliac patients. Clin Exp Immunol. 88:1992;6-9.
286. 1. J Virol. 73:1999;9274-9283.
287. Wiebush L., Hagemeier C. The human cytomegalovirus immediate early 2 protein dissociates cellular DNA synthesis from cyclin-dependent kinase activation. EMBO J. 20:2001;1086-1098.
288. Wiertz E.J., Jones T.R., Sun L., Bogyo M., Geuze H.J., Ploegh H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell. 84:1996;769-779.
289. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., Sissons J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 70:1996;7569-7579.
290. Winston D.J., Ho W.G., Bartoni K., Du Mond C., Ebeling D.F., Buhles W.C., Champlin R.E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 118:1993;179-184.
291. Wreghitt T.G., Hakim M., Gray J.J., Kucia S., Wallwork J., English T.A. Cytomegalovirus infections in heart and heart and lung transplantation. J Clin Pathol. 41:1988;660-667.
292. Yeager A.S., Martin H.P. Congenital cytomegalovirus infection: outcome for the subsequent sibling. Clin Pediatr. 16:1977;455-458.
293. Yurochko A.D., Kowalik T.F., Huong S.M., Huang E.-S. Human cytomegalovirus upregulates NF-κB activity by transactivating the NF-κB p105/p50 and p65 promoter. J Virol. 69:1995;5391-5400.
294. Yurochko A.D., Mayo M.W., Poma E.E., Baldwin A.S. Jr., Huang E.-S. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-κB promoters. J Virol. 71:1997;4638-4648.
295. Zanghellini F., Boppana S.B., Emery V.C., Griffiths P.D., Pass R.F. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis. 180:1999;702-707.
296. Zhu H., Shen Y., Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol. 69:1995;7960-7970.
297. Zhu H., Cong J.P., Shenk T. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of the interferon-responsive RNAs. Proc Natl Acad Sci USA. 94:1997;13985-13990.
298. Zhu H., Cong J.P., Mamtora G., Gingeras T., Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci USA. 95:1998;14470-14475.